Summary

Long-term disease control was observed with adalimumab administered in routine clinical practice to patients with moderately to severely active juvenile idiopathic arthritis (JIA). This article discusses interim findings from an analysis done at 4 years from an ongoing international registry of patients enrolled upon diagnosis of moderately to severely active JIA [NCT00783510].